{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:06:15Z","timestamp":1788930375575,"version":"build-2803163510"},"reference-count":24,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    To characterize the prevalence of\n                    <jats:italic>CYP2B6<\/jats:italic>\n                    and\n                    <jats:italic>OPRM1<\/jats:italic>\n                    gene polymorphisms and evaluate their associations with serum methadone concentrations and dose requirements in Vietnamese patients undergoing methadone maintenance treatment (MMT). This cross-sectional study enrolled 200 patients with opioid dependence from multiple MMT clinics in Ninh Binh, Vietnam, between October 2023 and March 2024. Demographic, clinical, and behavioral data were collected using structured questionnaires. Blood samples were obtained for genotyping\n                    <jats:italic>CYP2B6<\/jats:italic>\n                    (rs2279343 [785A&gt;G], rs3745274 [516G&gt;T], rs8192709 [64C&gt;T]) and\n                    <jats:italic>OPRM1<\/jats:italic>\n                    (A118G, rs1799971) using Sanger sequencing. Trough serum methadone concentrations were measured by validated liquid chromatography-tandem mass spectrometry (LC-MS\/MS). Multivariable linear regression was performed to identify clinical and genetic factors associated with serum methadone concentrations, the concentration-to-dose ratio (CDR), and maintenance methadone dose. Among 200 participants (99% male, 96.9% Kinh ethnicity), the most common\n                    <jats:italic>CYP2B6<\/jats:italic>\n                    diplotypes were *1\/*4 (33.3%) and *4\/*6 (23.7%), with the\n                    <jats:italic>OPRM1<\/jats:italic>\n                    AG genotype present in 47.5%. Most patients (53.5%) had been on methadone treatment for over 3 years. In multivariable regression, the *1\/*6 genotype was independently associated with lower maintenance dose (\u03b2 = \u221226.33, 95% CI: \u221251.97, \u22120.69). The *2\/*6 genotype was significantly associated with lower log serum methadone concentration (\u03b2 = \u22122.485, 95% CI: \u22123.024, \u22121.947) and lower log CDR (\u03b2 = \u22122.595, 95% CI: \u22123.145, \u22122.046). Most demographic, behavioral, and\n                    <jats:italic>OPRM1<\/jats:italic>\n                    genotypes showed no significant associations. Specific\n                    <jats:italic>CYP2B6<\/jats:italic>\n                    genotypes and SNPs significantly influence methadone pharmacokinetics in Vietnamese patients receiving MMT, although actual daily dose remains the most important determinant of serum levels. These findings highlight the potential role of genotype-guided methadone dosing in optimizing therapy for opioid dependence in Vietnamese populations.\n                  <\/jats:p>","DOI":"10.2478\/bjmg-2025-0010","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T05:00:13Z","timestamp":1759986013000},"source":"Crossref","is-referenced-by-count":1,"title":["Association of\n                    <i>CYP2B6<\/i>\n                    and\n                    <i>OPRM1<\/i>\n                    Genotypes with Methadone Dose Requirements and Serum Concentrations in a Vietnamese Cohorts"],"prefix":"10.2478","volume":"28","author":[{"given":"Quynh Giao","family":"Nguyen","sequence":"first","affiliation":[{"name":"Faculty Medical Technology, Hanoi Medical University , Hanoi , Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khanh Chi","family":"Tran","sequence":"additional","affiliation":[{"name":"Biochemistry Department , Hanoi Medical University , Hanoi , Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi Phuong Dung","family":"Trinh","sequence":"additional","affiliation":[{"name":"Faculty Medical Technology, Hanoi Medical University , Hanoi , Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huy Tan","family":"Pham","sequence":"additional","affiliation":[{"name":"Center for Family Medicine and Community Health Care , Hanoi Medical University Hospital , Hanoi , Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi Ngoc Dung","family":"Dang","sequence":"additional","affiliation":[{"name":"Biochemistry Department , Hanoi Medical University , Hanoi , Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"key":"2026042718353304360_j_bjmg-2025-0010_ref_001","doi-asserted-by":"crossref","unstructured":"Intishar K, Meghan JC, Didier JA, Keith A, Mar\u00eda Eugenia S, Bernard Le F, Rachel FT. Pharmacogenetics of Biochemically Verified Abstinence in an Opioid Agonist Therapy Randomized Clinical Trial of Methadone and Buprenorphine\/Naloxone. Clinical Pharmacology & Therapeutics. 2023;115(3):506\u2013514. doi:10.1002\/cpt.3112","DOI":"10.1002\/cpt.3112"},{"key":"2026042718353304360_j_bjmg-2025-0010_ref_002","doi-asserted-by":"crossref","unstructured":"Evan DK, Karen JR, Jane B, Christina F. Methadone Pharmacogenetics: CYP2B6 Polymorphisms Determine Plasma Concentrations, Clearance, and Metabolism. Anesthesiology. 2015;123(5):1142\u20131153. doi:10.1097\/ALN.0000000000000867","DOI":"10.1097\/ALN.0000000000000867"},{"key":"2026042718353304360_j_bjmg-2025-0010_ref_003","doi-asserted-by":"crossref","unstructured":"Hsin-Chou Y, Shih-Kai C, Shih-Kai C, et al. Genome-Wide Pharmacogenomic Study on Methadone Maintenance Treatment Identifies SNP rs17180299 and Multiple Haplotypes on CYP2B6, SPON1, and GSG1L Associated with Plasma Concentrations of Methadone R- and S-enantiomers in Heroin-Dependent Patients. PLOS Genetics. 2016;12(3) doi:10.1371\/JOURNAL.PGEN.1005910","DOI":"10.1371\/journal.pgen.1005910"},{"key":"2026042718353304360_j_bjmg-2025-0010_ref_004","doi-asserted-by":"crossref","unstructured":"Fitri Fareez R. Pharmacogenomics biomarkers for personalized methadone maintenance treatment: The mechanism and its potential use. Bosnian Journal of Basic Medical Sciences. 2020;21(2):145\u2013154. doi:10.17305\/BJBMS.2020.4897","DOI":"10.17305\/bjbms.2020.4897"},{"key":"2026042718353304360_j_bjmg-2025-0010_ref_005","doi-asserted-by":"crossref","unstructured":"Xiaohui X, Jun G, Dingding Z, et al. Association between rs1799971 in the mu opioid receptor gene and methadone maintenance treatment response. Journal of Clinical Laboratory Analysis. 2022;36(11) doi:10.1002\/jcla.24750","DOI":"10.1002\/jcla.24750"},{"key":"2026042718353304360_j_bjmg-2025-0010_ref_006","doi-asserted-by":"crossref","unstructured":"Sabina M, Rajabu Hussein M, Anna Alphonce S, et al. CYP2B6 and ABCB1 genotypes predict methadone plasma exposure among patients on maintenance therapy against opioid addictions in Tanzania. British Journal of Clinical Pharmacology. 2024;doi:10.1111\/bcp.16173","DOI":"10.1111\/bcp.16173"},{"key":"2026042718353304360_j_bjmg-2025-0010_ref_007","doi-asserted-by":"crossref","unstructured":"Fatemeh C, Lars Thore F, Kjell Arne J, et al. Methadone pharmacokinetics in opioid agonist treatment: Influencing factors and clinical implications. Basic & Clinical Pharmacology & Toxicology. 2023;doi:10.1111\/bcpt.13975","DOI":"10.1111\/bcpt.13975"},{"key":"2026042718353304360_j_bjmg-2025-0010_ref_008","doi-asserted-by":"crossref","unstructured":"Andrew HT, Yuxin D, Charles SV, et al. Toward precision prescribing for methadone: Determinants of methadone deposition. PLOS ONE. 2020;15(4) doi:10.1371\/JOURNAL.PONE.0231467","DOI":"10.1371\/journal.pone.0231467"},{"key":"2026042718353304360_j_bjmg-2025-0010_ref_009","doi-asserted-by":"crossref","unstructured":"Shuki Y, Eiji H, Yuma S, et al. Functional significance of CYP2B6 gene rare allelic variants identified in Japanese individuals. Biochemical Pharmacology. 2024;229:116515\u2013116515. doi:10.1016\/j.bcp.2024.116515","DOI":"10.1016\/j.bcp.2024.116515"},{"key":"2026042718353304360_j_bjmg-2025-0010_ref_010","doi-asserted-by":"crossref","unstructured":"Sheng-Chang W, Ing-Kang H, Hsiao-Hui T, et al. CYP2B6 polymorphisms influence the plasma concentration and clearance of the methadone S-enantiomer. Journal of Clinical Psychopharmacology. 2011;31(4):463\u2013469. doi:10.1097\/JCP.0B013E318222B5DD","DOI":"10.1097\/JCP.0b013e318222b5dd"},{"key":"2026042718353304360_j_bjmg-2025-0010_ref_011","doi-asserted-by":"crossref","unstructured":"Yen-Jung C, Ju-Ting L, Chun-Wei H, Wei-Hsin W, Kuei-Fang L, Hsin-Tzu L, Lawrence Shih-Hsin W. Pharmacogenetic study of methadone treatment for heroin addiction: associations between drug-metabolizing gene polymorphisms and treatment efficacy. Pharmacogenetics and Genomics. 2022;32(1):31\u201338. doi:10.1097\/FPC.0000000000000450","DOI":"10.1097\/FPC.0000000000000450"},{"key":"2026042718353304360_j_bjmg-2025-0010_ref_012","doi-asserted-by":"crossref","unstructured":"David T, Britt ID, Galen EBW, et al. Characterisation of CYP2B6 and CYP2A6 pharmacogenetic variation in sub-Saharan African populations. Klini\u010deska\u00e2 farmakologi\u00e2 i terapi\u00e2. 2023;doi:10.1002\/cpt.3124","DOI":"10.1002\/cpt.3124"},{"key":"2026042718353304360_j_bjmg-2025-0010_ref_013","doi-asserted-by":"crossref","unstructured":"Bunten H, Wei-Jun L, Derrick JP, Collin S, Osselton D. OPRM1 and CYP2B6 gene variants as risk factors in methadone-related deaths. Clinical Pharmacology & Therapeutics. 2010;88(3):383\u2013389. doi:10.1038\/CLPT.2010.127","DOI":"10.1038\/clpt.2010.127"},{"key":"2026042718353304360_j_bjmg-2025-0010_ref_014","doi-asserted-by":"crossref","unstructured":"Chin-Chuan H, Mu-Han C, Bo-Hau H, Yow-Wen H, Tsung-Jen H, Chieh-Liang H, Hsien-Yuan L. Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients. Pharmacogenomics. 2011;12(11):1525\u20131533. doi:10.2217\/PGS.11.96","DOI":"10.2217\/pgs.11.96"},{"key":"2026042718353304360_j_bjmg-2025-0010_ref_015","doi-asserted-by":"crossref","unstructured":"Sadat Aghabozorg Afjeh S, Boshehri B, Hamednia S, Amini A, Mashayekhi P, Omrani MD. Investigating the CYP2B6 rs3745274 and rs3211371 polymorphisms in Methadone-Responder and Non-Responder Addicts in Iran. Iran Biomed J. Feb 6 2021;25(3):220\u20135. doi:10.29252\/ibj.25.3.220","DOI":"10.52547\/ibj.25.3.220"},{"key":"2026042718353304360_j_bjmg-2025-0010_ref_016","doi-asserted-by":"crossref","unstructured":"Bunten H, Wei-Jun L, Derrick JP, Collin S, Osselton D. Interindividual variability in the prevalence of OPRM1 and CYP2B6 gene variations may identify drug-susceptible populations. Journal of Analytical Toxicology. 2011;35(7):431\u2013437. doi:10.1093\/ANATOX\/35.7.431","DOI":"10.1093\/anatox\/35.7.431"},{"key":"2026042718353304360_j_bjmg-2025-0010_ref_017","doi-asserted-by":"crossref","unstructured":"Sarah G, Christina F, Evan DK. Differences in Methadone Metabolism by CYP2B6 Variants. Drug Metabolism and Disposition. 2015;43(7):994\u20131001. doi:10.1124\/DMD.115.064352","DOI":"10.1124\/dmd.115.064352"},{"key":"2026042718353304360_j_bjmg-2025-0010_ref_018","doi-asserted-by":"crossref","unstructured":"Maria D, S\u00e9verine C, Beatrice O, et al. Contribution of CYP2B6 alleles in explaining extreme (S)-methadone plasma levels: a CYP2B6 gene resequencing study. Pharmacogenetics and Genomics. 2013;23(2):84\u201393. doi:10.1097\/FPC.0B013E32835CB2E2","DOI":"10.1097\/FPC.0b013e32835cb2e2"},{"key":"2026042718353304360_j_bjmg-2025-0010_ref_019","doi-asserted-by":"crossref","unstructured":"Chantal C, S\u00e9verine C, Monia G, Chin BE. Population Genetic-Based Pharmacokinetic Modeling of Methadone and its Relationship with the QTc Interval in Opioid-Dependent Patients. Clinical Pharmacokinectics. 2016;55(12):1521\u20131533. doi:10.1007\/S40262-016-0415-2","DOI":"10.1007\/s40262-016-0415-2"},{"key":"2026042718353304360_j_bjmg-2025-0010_ref_020","doi-asserted-by":"crossref","unstructured":"Xueying Z, Yongxin L, Nannan Z, et al. The Relevance of the OPRM1 118A>G Genetic Variant for Opioid Requirement in Pain Treatment: A Meta-Analysis. Pain Physician. 2019;22(4):331\u2013340. doi:10.36076\/PPJ\/2019.22.331","DOI":"10.36076\/ppj\/2019.22.331"},{"key":"2026042718353304360_j_bjmg-2025-0010_ref_021","doi-asserted-by":"crossref","unstructured":"Miho T, Kazuyuki N, Yoshiaki O, Tomohiro K, Makie K, Yoshinobu M, Kenji I. Comparison of the effects of OPRM1 A118G polymorphism using different opioids: A prospective study. Journal of Pain and Symptom Management. 2023;doi:10.1016\/j.jpainsymman.2023.09.017","DOI":"10.1016\/j.jpainsymman.2023.09.017"},{"key":"2026042718353304360_j_bjmg-2025-0010_ref_022","doi-asserted-by":"crossref","unstructured":"Andrew HS, Kevin PJ, Jin L, et al. Genome-wide association study of therapeutic opioid dosing identifies a novel locus upstream of OPRM1. Molecular Psychiatry. 2017;22(3):346\u2013352. doi:10.1038\/MP.2016.257","DOI":"10.1038\/mp.2016.257"},{"key":"2026042718353304360_j_bjmg-2025-0010_ref_023","doi-asserted-by":"crossref","unstructured":"Kelly ED, Andrew SH, Patrick HF, et al. Polymorphisms in the A118G SNP of the OPRM1 gene produce different experiences of opioids: A human laboratory phenotype\u2013genotype assessment. Addiction Biology. 2023;doi:10.1111\/adb.13355","DOI":"10.1111\/adb.13355"},{"key":"2026042718353304360_j_bjmg-2025-0010_ref_024","doi-asserted-by":"crossref","unstructured":"Yihan X, Julie AB. Neural network connectivity following opioid dependence is altered by a common genetic variant in the mu-opioid receptor,OPRM1A118G. The Journal of Neuroscience. 2023;doi:10.1523\/jneurosci.1492-23.2023","DOI":"10.1523\/JNEUROSCI.1492-23.2023"}],"container-title":["Balkan Journal of Medical Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/bjmg-2025-0010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T21:45:32Z","timestamp":1777326332000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/bjmg-2025-0010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,1]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,10,8]]},"published-print":{"date-parts":[[2025,6,1]]}},"alternative-id":["10.2478\/bjmg-2025-0010"],"URL":"https:\/\/doi.org\/10.2478\/bjmg-2025-0010","relation":{},"ISSN":["2199-5761"],"issn-type":[{"value":"2199-5761","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,1]]},"article-number":"20250010"}}